ReviewBiosensors & bioelectronics2016
Nano-biosensors to detect beta-amyloid for Alzheimer's disease management.
Review in Biosensors & bioelectronics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 166 citations in OpenAlex.
- Extraoral Detection of Biomarkers and Pathogens in Saliva: Comprehensive, Panoramic Review.Biosensors · 2026Review
- Nano-based spectroscopic approaches for early diagnosis of Alzheimer's disease: critical insights into amyloid-β and tau biomarker biology and detection tools.Biophysical reviews · 2026Review
- Recent Advancements in Biosensors for the Detection and Characterization of Amyloids: A Review.The protein journal · 2024Review
- Label-free detection of Aβ-42: a liquid crystal droplet approach for Alzheimer's disease diagnosis.RSC advances · 2024Article
- Miniaturized, high numerical aperture confocal fluorescence detection enhanced with pyroelectric droplet accumulation for sub-attomole analyte diagnosis.Biomedical optics express · 2023Article
- Review
- An Updated Review on Electrochemical Nanobiosensors for Neurotransmitter Detection.Biosensors · 2023Review
- Electrochemical Immunosensor for Early Detection of β-Amyloid Alzheimer's Disease Biomarker Based on Aligned Carbon Nanotubes Gold Nanocomposites.Biosensors · 2022Article
- Acoustofluidic multimodal diagnostic system for Alzheimer's disease.Biosensors & bioelectronics · 2022Article
- Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond.RSC advances · 2021Review
- The perspectives of biomarker-based electrochemical immunosensors, artificial intelligence and the Internet of Medical Things toward COVID-19 diagnosis and management.Materials today. Chemistry · 2021Review
- Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases.Biosensors & bioelectronics · 2021Review
- Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer's Disease in Blood.Frontiers in molecular neuroscience · 2021Review
- Nanobiosensors for Non-Amyloidbeta-Tau Biomarkers as Advanced Reporters of Alzheimer's Disease.Diagnostics (Basel, Switzerland) · 2020Review
- Nano-enabled biosensing systems for intelligent healthcare: towards COVID-19 management.Materials today. Chemistry · 2020Review
- Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer's Disease.Sensors (Basel, Switzerland) · 2020Review
- On-Chip Detection of the Biomarkers for Neurodegenerative Diseases: Technologies and Prospects.Micromachines · 2020Review
- Paper-Based Detection Device for Alzheimer's Disease-Detecting β-amyloid Peptides (1-42) in Human Plasma.Diagnostics (Basel, Switzerland) · 2020Article
- Potential of Microfluidics and Lab-on-Chip Platforms to Improve Understanding of "Frontiers in bioengineering and biotechnology · 2020Review
- Alzheimer's disease: pathogenesis, diagnostics, and therapeutics.International journal of nanomedicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Beta-amyloid (β-A) peptides are potential biomarkers to monitor Alzheimer's diseases (AD) for diagnostic purposes. Increased β-A level is neurotoxic and induces oxidative stress in brain resulting in neurodegeneration and causes dementia. As of now, no sensitive and inexpensive method is available for β-A detection under physiological and pathological conditions. Although, available methods such as neuroimaging, enzyme-linked immunosorbent assay (ELISA), and polymerase chain reaction (PCR) detect β-A, but they are not yet extended at point-of-care (POC) due to sophisticated equipments, need of high expertize, complicated operations, and challenge of low detection limit. Recently, β-A antibody based electrochemical immuno-sensing approach has been explored to detect β-A at pM levels within 30-40 min compared to 6-8h of ELISA test. The introduction of nano-enabling electrochemical sensing technology could enable rapid detection of β-A at POC and may facilitate fast personalized health care delivery. This review explores recent advancements in nano-enabling electrochemical β-A sensing technologies towards POC application to AD management. These analytical tools can serve as an analytical tool for AD management program to obtain bio-informatics needed to optimize therapeutics for neurodegenerative diseases diagnosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.